Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Tips and Tricks and Clinical Outcome of Cryopreserved Human Amniotic Membrane Application for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Pilot Study

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Service de Chirurgie Maxillo-Faciale et Stomatologie; Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon); Nanomédecine, imagerie, thérapeutique - UFC (UR 4662) (NIT / NANOMEDECINE); Université de Franche-Comté (UFC); Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC); Biospectroscopie Translationnelle - EA 7506 (BIOSPECT); Université de Reims Champagne-Ardenne (URCA); Hémostase et Remodelage Vasculaire Post-Ischémie (HERVI - EA 3801); Service Chirurgie Maxillo-Faciale - Stomatologie - Chirurgie Plastique Réparatrice et Esthétique - Chirurgie de la main (CHU de Dijon); Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); Biomatériaux et inflammation en site osseux - EA 4691 (BIOS); Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-SFR CAP Santé (Champagne-Ardenne Picardie Santé); Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA); Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER); Institut Pasteur de Lille; Pasteur Network (Réseau International des Instituts Pasteur)-Pasteur Network (Réseau International des Instituts Pasteur)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS); Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT); Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang Bourgogne-Franche-Comté (EFS BFC)-Université de Franche-Comté (UFC); Biothérapies des maladies génétiques et cancers; Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM); Bioingénierie tissulaire (BIOTIS); Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre d'Investigation Clinique de Besançon (Inserm CIC 1431); Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang Bourgogne-Franche-Comté (EFS BFC)-Université de Franche-Comté (UFC)
    • Publication Information:
      CCSD
      Frontiers
    • Publication Date:
      2022
    • Collection:
      Université de Franche-Comté (UFC): HAL
    • Abstract:
      International audience ; Medication-related osteonecrosis of the jaw (MRONJ) is a complication of certain pharmacological treatments such as bisphosphonates, denosumab, and angiogenesis inhibitors. There are currently no guidelines on its management, particularly in advanced stages. The human amniotic membrane (hAM) has low immunogenicity and exerts anti-inflammatory, antifibrotic, antimicrobial, antiviral, and analgesic effects. It is a source of stem cells and growth factors promoting tissue regeneration. hAM acts as an anatomical barrier with suitable mechanical properties (permeability, stability, elasticity, flexibility, and resorbability) to prevent the proliferation of fibrous tissue and promote early neovascularization at the surgical site. In oral surgery, hAM stimulates healing and facilitates the proliferation and differentiation of epithelial cells in the oral mucosa and therefore its regeneration. We proposed using cryopreserved hAM to eight patients suffering from cancer (11 lesions) with stage 2–3 MRONJ on a compassionate use basis. A collagen sponge was added in some cases to facilitate hAM grafting. One or three hAMs were applied and one patient had a reapplication. Three patients had complete closure of the surgical site with proper epithelialization at 2 weeks, and two of them maintained it until the last follow-up. At 1 week after surgery, three patients had partial wound dehiscence with partial healing 3 months later and two patients had complete wound dehiscence. hAM reapplication led to complete healing. All patients remained asymptomatic with excellent immediate significant pain relief, no infections, and a truly positive impact on the patients’ quality of life. No adverse events occurred. At 6 months of follow-up, 80% of lesions had complete or partial wound healing (30 and 50%, respectively), while 62.5% of patients were in stage 3. Radiological evaluations found that 85.7% of patients had stable bone lesions ( n = 5) or new bone formation ( n = 1). One patient had a worsening MRONJ but ...
    • Accession Number:
      10.3389/fbioe.2022.936074
    • Online Access:
      https://hal.univ-reims.fr/hal-03772026
      https://hal.univ-reims.fr/hal-03772026v1/document
      https://hal.univ-reims.fr/hal-03772026v1/file/Odet%20et%20al.%20%282022%29%20-%20Tips%20and%20Tricks%20and%20Clinical%20Outcome%20of%20Cryopreserved%20Human%20Amniotic%20Membrane%20Application.pdf
      https://doi.org/10.3389/fbioe.2022.936074
    • Rights:
      http://creativecommons.org/licenses/by/ ; info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.38D7D97F